Latest Conference Articles

Dr Matous on the Use Talquetamab/Pomalidomide in Relapsed/Refractory Multiple Myeloma

Jeffrey Matous, MD, discusses outcomes from the phase 1b MonumenTAL-2 trial with the combination of talquetamab and pomalidomide in patients with relapsed/refractory multiple myeloma.

Dr Cohen on the Efficacy of Pirtobrutinib in High-Risk Patients With MCL

Jonathon B. Cohen, MD, MS, discusses safety and efficacy outcomes with pirtobrutinib in previously treated patients with relapsed/refractory mantle cell lymphoma, as observed in the phase 1/2 BRUIN study.

BGB-16673 Delivers Responses With a Tolerable Safety Profile Across R/R B-Cell Malignancies

The novel BTK degrader BGB-16673 was well tolerated; produced meaningful and rapid clinical responses; and demonstrated on-target effects in patients with relapsed/refractory B-cell malignancies.

Revumenib Elicits High Response Rate in R/R KMT2A-Rearranged Acute Leukemia

Revumenib demonstrated clinically meaningful activity, including high response and minimal residual disease negativity rates, in heavily pretreated patients with KMT2A-rearranged acute leukemia.

D-VRd Improves PFS in Newly Diagnosed, Transplant-Eligible Multiple Myeloma

Induction therapy with subcutaneous daratumumab followed by autologous stem cell transplant, daratumumab, bortezomib, lenalidomide, and dexamethasone consolidation and daratumumab/lenalidomide maintenance prolonged progression-free survival in patients with newly diagnosed, transplant-eligible multiple myeloma.

Ibrutinib Plus Venetoclax Confers PFS, Response Benefit in Relapsed/Refractory MCL

Treatment with the oral BTK inhibitor ibrutinib in combination with venetoclax led to a statistically significant improvement in progression-free survival vs ibrutinib plus placebo in patients with relapsed/refractory MCL.

Financial Navigation Program May Alleviate Cost Burden Associated With Multiple Myeloma

Utilization of a financial navigation program is feasible for reducing cost burden and improving quality of life in patients with multiple myeloma who are more likely to experience financial toxicity and have difficulty accessing appropriate resources and support services.

Anito-Cel Elicits Responses With Manageable Safety in Relapsed/Refractory Multiple Myeloma

Anitocabtagene autoleucel showcased early efficacy with acceptable toxicity in patients with relapsed and/or refractory multiple myeloma—even in those with high-risk features.

Talquetamab Dose Modifications May Lower AEs While Maintaining Efficacy in R/R Multiple Myeloma

Dose modifications of talquetamab improved on-target adverse effects while maintaining responses for patients with relapsed/refractory multiple myeloma.

NX-2127 Elicits Responses With Manageable Safety in Heavily Pretreated B-cell Malignancies

NX-2127 showcased early efficacy in the form of responses with an acceptable toxicity profile in patients with relapsed or refractory B-cell malignancies, according to data from the ongoing phase 1 NX-2127-001 trial.

Looking at the Latest Data in Multiple Myeloma and Lymphoma From ASH 2023: Drs Landgren and Saeed

Orca-Q Showcases Early Efficacy, Acceptable Safety in Haploidentical Stem Cell Transplant Without PTCy

The high-precision cellular product Orca-Q demonstrated early signals of clinical activity as well as an acceptable safety profile for patients undergoing haploidentical stem cell transplantation without posttransplant cyclophosphamide.

Dr Andorsky on Real-World Treatment Patterns With BTK Inhibitors in CLL/SLL

David J. Andorsky, MD, discusses recently observed patterns of care with BTK inhibitors in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in the community setting in the United States, and how social determinants of health may have affected these outcomes.

Dr Rampal on Findings From the MANIFEST-2 Trial in JAK Inhibitor–Naive Myelofibrosis

Raajit K. Rampal, MD, PhD, discusses findings from the phase 3 MANIFEST-2 trial investigating pelabresib in combination with ruxolitinib for JAK inhibitor–naive patients with myelofibrosis.

Zanubrutinib Triplet Shows Early Promise in Treatment-Naive TP53-Mutant MCL

The combination comprised of zanubrutinib, obinutuzumab, and venetoclax elicited high response rates and 2-year progression-free survival rates that compared favorably with historical outcomes achieved with chemoimmunotherapy in high-risk patients with previously untreated mantle cell lymphoma harboring TP53 mutations.

Zanubrutinib May Be Viable Option After Acalabrutinib Intolerance in B-Cell Malignancies

Patients with B-cell malignancies who were intolerant to treatment with acalabrutinib experienced clinically meaningful benefits when treated with zanubrutinib, suggesting zanubrutinib may be a viable treatment option for this population.

Pelabresib/Ruxolitinib Combo Improves Splenomegaly, TSS in JAK Inhibitor–Naive Myelofibrosis

Pelabresib plus ruxolitinib demonstrated a 35% or greater reduction in spleen volume and trended toward reducing mean absolute total symptom score (TSS) as well as improving TSS reduction by 50% at 24 weeks in patients with JAK inhibitor–naive myelofibrosis.

Tisagenlecleucel Yields Durable Responses in R/R Follicular Lymphoma

Patients with relapsed/refractory follicular lymphoma experienced durable responses when treated with tisagenlecleucel (Kymriah) in the phase 2 ELARA study (NCT03568461), according to data presented at the 2023 ASH Annual Meeting.

Ruxolitinib Shows Sustained Efficacy Over Best Available Therapy in Steroid-Refractory/Dependent cGVHD

Treatment with ruxolitinib led to prolonged failure-free survival and improved disease control vs best available treatment in patients with either steroid-refractory or -dependent chronic graft-vs-host disease.

NX-1607 Is Under Phase 1 Evaluation in DLBCL and Other Advanced Malignancies

The phase 1a/1b NX-1607-101 trial will evaluate NX-1607, a CBL-B inhibitor, in patients with advanced malignancies, including diffuse large B-cell lymphoma.

Pirtobrutinib Monotherapy Demonstrates Early Activity in R/R Follicular Lymphoma

Treatment with single-agent pirtobrutinib showed encouraging efficacy with a tolerable safety profile in a cohort of heavily pretreated patients with relapsed/refractory follicular lymphoma.

Final APPLY-PNH Data Support Use of Iptacopan in PNH With Persistent Anemia

Oral iptacopan (Fabhalta) monotherapy induced durable responses and hemolysis control in patients with paroxysmal nocturnal hemoglobinuria and persistent anemia who had previously received anti-C5 treatment.

Brentuximab Vedotin Combo Elicits Responses in Advanced Classical Hodgkin Lymphoma

Brentuximab vedotin plus nivolumab, doxorubicin, and dacarbazine was found to have efficacy and acceptable safety and tolerability when used as a frontline treatment in patients with previously untreated advanced, classical Hodgkin lymphoma.

Acalabrutinib With or Without Obinutuzumab Provides Sustained PFS Benefit in Previously Untreated CLL

Acalabrutinib, as monotherapy or in combination with obinutuzumab, continued to improve progression-free survival vs obinutuzumab and chemotherapy in patients with treatment-naive chronic lymphocytic leukemia, regardless of genomic marker status.

Making the Most of New Data in MPN, Leukemia, and GVHD From ASH 2023: Drs Ponce and Hobbs

Isa-KRd Significantly Improves MRD Negativity Rates at Cutoffs Vs KRd in Newly Diagnosed Multiple Myeloma

The combination of Isa-KRd significantly increased the rates of minimal residual disease negativity at cutoffs post-consolidation vs KRd in patients with newly diagnosed multiple myeloma.

Axatilimab Elicits Responses With Manageable Safety in Recurrent/Refractory cGVHD

Axatilimab induced rapid and durable responses with an acceptable toxicity profile at all doses analyzed with highest efficacy observed at the 0.3-mg/kg dose in patients with recurrent or refractory chronic graft-vs-host disease.

Dr Bal on Updated Findings With BMS-986393 in Relapsed/Refractory Multiple Myeloma

Susan Bal, MD, discusses updated safety and efficacy data from a phase 1 study evaluating the GPRC5D-targeted autologous CAR T-cell therapy BMS-986393 in relapsed/refractory multiple myeloma, including in patients with prior BCMA-directed therapy.

Dr Ghia on a Biomarker Analysis of the SEQUOIA Trial in CLL/SLL

Paolo Ghia, MD, PhD, full professor, discusses a biomarker subgroup analysis of the phase 3 SEQUOIA trial investigating zanubrutinib vs bendamustine plus rituximab in patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma without 17p deletions.

Oral DEC-C Treatment Is Feasible and Comparable With IV/SC HMA Outcomes in MDS

Oral decitabine/cedazuridine and parenteral hypomethylating agents were associated with similar levels of comorbidities and disease burden in patients with myelodysplastic syndrome.